Anusha Ramachandran
Director of CMC Operations Convergent Therapeutics, Inc
Wednesday 16th September 2026
Securing Actinium Supply Through Emerging Production Pathways & Strategic Partnerships to Overcome the Alpha Isotope Bottleneck
10:00 am
- Exploring emerging production pathways (thorium extraction, accelerator-based methods, reactor routes) and assessing their scalability and commercial viability
- Strategizing long-term supply agreements and partnership models to secure access to Ac-225 in a competitive and supply-constrained environment
- Managing quality and regulatory considerations associated with Ac-225 production, including handling impurities such as Ac-227 and downstream QC implications
Wednesday 16th September 2026
Panel Discussion: Why 2026 Is the Year the Gap Between Clinical Ambition & Operational Capacity Must Begin to Close
9:15 am
- Panelists will examine the state of the radiopharmaceutical supply chain in 2026: where infrastructure investment is landing, where the workforce deficit is most acute, and how the shift in isotope preferences – from the established beta emitters toward alphas and emerging candidates – is creating new pressure across every manufacturing echelon
- Discussing the compounding risks that arise as programs progress into Phase II/III, where reliance on limited isotope supply, third-party manufacturing, logistics, and fragmented coordination from CDMO through to bedside must be managed in parallel to avoid disruption to clinical delivery
- Discuss what ‘commercial readiness’ actually means for radiopharmaceuticals and why the industry’s collective definition has to evolve beyond approval to include reliable, scalable, and distributed supply at the patient level
